Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00946569 · ClinicalTrials.gov registry record · Phase 2
A Study of the Safety and Effectiveness of JNJ-39758979 in the Treatment of Adults With Persistent Asthma
A Phase 2 study of Asthma, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
- 20
- Study locations
NCT00946569: Completed Phase 2 study of Asthma, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
NCT00946569 is a Phase 2 study of Asthma that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 116 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00946569, a Phase 2 study of Asthma, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of once daily oral administration of JNJ-39758979 in the treatment of adults (18 to 65 years of age) with persistent asthma.
Primary Outcome
FEV1 will be measured by using spirometry test. Spirometry is used to measure lung function, specifically the amount (volume) and/or speed (flow) of air that can be inhaled and exhaled. Lung volumes will be measured according to the body temperature, pressure, and saturated standard convention using the spirometer. Pre-bronchodilator spirometry will be performed in the absence of albuterol/salbutamol or at least 6 hours after the last dose of albuterol/salbutamol.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG JNJ39758979
Study Locations (20)
California
- - Cypress
- - Los Angeles
- - San Diego
Ontario
- - Niagara Falls
- - Ottawa
- - Toronto
Oregon
- - Medford
- - Portland
Texas
- - Dallas
- - Waco
Arizona
- - Scottsdale
Illinois
- - Normal
Massachusetts
- - North Dartmouth
Nebraska
- - Papillion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2009-08 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
What the finished NCT00946569 record still lists
NCT00946569 is an interventional study that assigns participants to a tested intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00946569 names 20 study sites across 14 states, led by California, Ontario, Oregon.
Frequently Asked Questions
What is clinical trial NCT00946569 about?
NCT00946569 is a clinical study titled "A Study of the Safety and Effectiveness of JNJ-39758979 in the Treatment of Adults With Persistent Asthma". The purpose of this study is to evaluate the safety and effectiveness of once daily oral administration of JNJ-39758979 in the treatment of adults (18 to 65 years of age) with persistent asthma.
What is the current status of trial NCT00946569?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2009-08. Estimated completion is 2010-09.
What conditions does trial NCT00946569 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00946569?
The interventions under investigation include: Placebo (DRUG), JNJ39758979 (DRUG).
Who is sponsoring clinical trial NCT00946569?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00946569 being conducted?
This trial has 20 study locations across Arizona, California, Illinois, Massachusetts, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00946569's enrollment target sits among peer trials
116 204th of 374 higher than 171 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03014687 · 116 participants · Phase 4
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
- NCT03214562 · 116 participants · Phase 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- NCT03847467 · 116 participants · Phase 1
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
- NCT04222413 · 116 participants · Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia